

Malaysia

Population 2018

32 million

Estimates of TB burden ^o , 2018	Number (thousands)	Rate (per 100 000 population)
Total TB incidence	29 (25–33)	92 (79–106)
HIV-positive TB incidence	1.9 (1.6–2.2)	5.9 (5–6.9)
MDR/RR-TB incidence ^{oo}	0.48 (0.36–0.62)	1.5 (1.1–2)
HIV-negative TB mortality	1.2 (1.1–1.4)	3.9 (3.5–4.3)
HIV-positive TB mortality	0.32 (0.24–0.42)	1 (0.75–1.3)

Estimated proportion of TB cases with MDR/RR-TB, 2018

New cases	1.5% (1.2–1.9)
Previously treated cases	3.1% (1.3–5.9)

TB case notifications, 2018

Total new and relapse	25 173
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	81%
- % pulmonary	85%
- % bacteriologically confirmed ^{ooo}	73%
- % children aged 0–14 years	2%
- % women	35%
- % men	63%
Total cases notified	25 837

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2018	87% (75–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2018	5% (4–6)

TB/HIV care in new and relapse TB patients, 2018

	Number	(%)
Patients with known HIV status who are HIV-positive	1 319	6%
- on antiretroviral therapy	402	30%

Drug-resistant TB care, 2018

% of bacteriologically confirmed TB cases tested for rifampicin resistance ^{ooo}	
- New cases	78%
- Previously treated cases	78%
Laboratory-confirmed cases*	MDR/RR-TB: 192, XDR-TB: 1
Patients started on treatment**	MDR/RR-TB: 137, XDR-TB: 1
MDR/RR-TB cases tested for resistance to second-line drugs	145

Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2017	81%	24 810
Previously treated cases, excluding relapse, registered in 2017	52%	704
HIV-positive TB cases registered in 2017	58%	1 302
MDR/RR-TB cases started on second-line treatment in 2016	49%	71
XDR-TB cases started on second-line treatment in 2016		0

TB preventive treatment, 2018

% of HIV-positive people (newly enrolled in care) on preventive treatment	38%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	88% (65–100)

TB financing, 2019

National TB budget (US\$ millions)	16
Funding source: 100% domestic, international, 0% unfunded	

^o Ranges represent uncertainty intervals

^{oo} MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin


^{ooo} Calculated for pulmonary cases only

* Includes cases with unknown previous TB treatment history

** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




Legend:
■ Total TB incidence
■ New and relapse TB cases notified
■ HIV-positive TB incidence

(Rate per 100 000 population per year)




Legend:
■ HIV-negative TB mortality

Notified cases by age group and sex, 2018




Legend:
■ Females ■ Males Incidence

Treatment success rate (%)



Legend:
■ New and relapse
■ Retreatment, excluding relapse
■ HIV-positive ■ MDR/RR-TB ■ XDR-TB

Total budget (US\$ millions)



Legend:
■ Unfunded
■ Funded internationally
■ Funded domestically